- Investing.com
Metrics to compare | WWB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWWBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −24.3x | −1.5x | −0.2x | |
PEG Ratio | - | −0.01 | 0.00 | |
Price/Book | 6.2x | 0.7x | 2.6x | |
Price / LTM Sales | - | 5.3x | 2.8x | |
Upside (Analyst Target) | - | 457.1% | 65.0% | |
Fair Value Upside | Unlock | 23.0% | 9.6% | Unlock |
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.